Searchicon: search

Nobivac® NXT Canine Flu H3N2

Discover the next (NXT) generation of protection. Nobivac® NXT Canine Flu H3N2 is a groundbreaking new way to safeguard dogs against the ongoing threat of canine flu with revolutionary RNA particle technology.1

icon: canine

Product Description

Discover the first and only canine influenza vaccine to use RNA particle technology to generate an efficient, comprehensive immune response.

product Label

Overview

Technical

Features & Benefits

RNA particle technology

  • RNA particles stimulate the immune system to attack the H3N2 virus without the use of adjuvants or live organisms

Multi-layered Immunity

  • Enhances the body’s natural processes to induce innate, humoral, and cellular immunity

Smaller dose

  • A low-volume 0.5 mL dose provides a more gentle vaccine experience.

No extraneous material

  • Nobivac® NXT-level protection in a preservative-free, adjuvant-free, thimerosal-free formulation.

How It Works

Discover the science behind Nobivac® NXT-level RNA particle technology. See how this revolutionary new way of delivering protection provides an exciting new option for you and your patients.

Downloads

icon: download

NOBIVAC® NXT Canine Flu H3N2

icon: arrow-rightDownload
icon: download

Your guide to the prevention and management of canine influenza virus

Addressing Canine Influenza

Use this brochure to help guide your practice in the identification, containment, and prevention of CIV outbreaks.

icon: arrow-rightDownload

Uncompromising Safety and Efficacy

SIGNIFICANTLY REDUCES COUGHING AND LUNG LESION SCORES (P<0.0001)

*The standardized method of evaluating efficacy of canine influenza vaccines is based on lung lobe consolidation.2

† Two doses of Nobivac® NXT Canine Flu H3N2 were administered to 8-week-old puppies, subcutaneously, 3 weeks apart. Challenge was conducted 2 weeks post 2nd vaccination. Clinical observations were recorded for 10 days post-challenge, and nasal swabs were collected for 10 consecutive days to determine viral shedding. Lungs were evaluated 10 days following challenge.

‡ P<0.0001

SIGNIFICANTLY REDUCES THE DURATION OF VIRAL SHEDDING.

§Two doses of Nobivac® NXT Canine Flu H3N2 were administered to 8-week-old puppies, subcutaneously, 3 weeks apart. Challenge was conducted 2 weeks post 2nd vaccination. Clinical observations were recorded for 10 days post-challenge, and nasal swabs were collected for 10 consecutive days to determine viral shedding. Lungs were evaluated 10 days following challenge.

|| Magnitude of viral shedding on Day 1 – P=0.0001

¶ Overall duration of viral shedding and magnitude of viral shedding – P<0.0001

PROVEN SAFE ACROSS A VARIETY OF BREEDS AND AGES.

A field safety study proved Nobivac® NXT Canine Flu H3N2 to be well tolerated in a wide range of canine patients1

  • 1,301 doses administered to 654 dogs of various breeds
  • Dogs ranged in age from 8 weeks to 15 years
  • Lethargy was the most common adverse event (1.6%)

DISEASE INFORMATION

CANINE INFLUENZA VIRUS

Canine influenza virus (CIV) causes a respiratory infection in dogs that is also known as dog flu. The infection is very contagious to other dogs. Laboratory surveillance indicates the H3N2 strain of CIV as the critical strain of concern.1

Following vaccination with Nobivac® Lyme, no B. burgdorferi were found.

TRANSISSION / CLINICAL SIGNS

Transmission

  • Direct contact (licking, nuzzling)
  • Indirect (coughing or sneezing)
  • Contaminated surfaces such as food and water bowls, cages
  • Human contact

Clinical Signs

  • Coughing (dry or moist)
  • Sneezing
  • Fever
  • Nasal discharge
  • Lack of energy
  • Loss of appetite

RISK FACTORS

Risk Factors

  • Dogs that come from shelters, rescue centers, breeding kennels, or pet stores
  • Boarding at a kennel or doggie daycare
  • Visiting groomers, dog parks, or engaging with other dogs
  • Dogs that participate in events/competitions
  • Dogs that travel
  • Dogs of veterinary staff that may be exposed through contaminated fomites
  • Sharing an elevator or other confined space with other dogs

NOBIVAC® NXT-GENERATION PROTECTION

Learn more about Nobivac® NXT technology, the latest vaccine platform from Nobivac®.

LEARN MORE

References

  1. Data on file. Merck Animal Health.
  2. Deshpande MS, Jirjis FF, Tubbs AL, et al. Evaluation of the efficacy of a canine influenza virus H3N8 vaccine in dogs following experimental challenge. Vet Therapeut. 2009;10(3): 103-112.